Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects.
Hong-Yu LuoShuo-Guo XuLi-Chen GaoHui-Zhi LongZi-Wei ZhouFeng-Jiao LiShang-Ming DaiJin-Da HuYu SuYan ChengPublished in: Drugs in R&D (2024)
The concentration of bismuth in the blood of healthy subjects in the T formulation was not greater than that in the R formulation. Similarly, the safety of oral administration of 120 mg of bismuth potassium citrate formulations to healthy subjects was good. The trial registration number (TRN) was [2018] 013, 6 December 2018.